OHSU Knight Cancer Institute: Lymphoma trials

The registry lists 16 Lymphoma studies with OHSU Knight Cancer Institute as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 4Phase 2 11Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell LymphomaCompletedNCT02736617Phase 2Results posted
• Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell LymphomaTerminatedNCT01397591Phase 2Results posted
• Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's LymphomaCompletedNCT00764517Phase 2Results posted
• Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin LymphomaTerminatedNCT00691652Phase 1/2Results posted
• Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic CancerTerminatedNCT00281879Phase 2Results posted
• Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00245037Phase 1/2Results posted
• Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's LymphomaCompletedNCT00238433Phase 2Results posted
• Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment RegimenTerminatedNCT00074165Phase 2Results posted
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Blood Samples From Patients on a Clinical Trial to CINV During HSCTTerminatedNCT00900068
• Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term SurvivorsTerminatedNCT00710151
• Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell TransplantTerminatedNCT00324324Phase 3
• Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System LymphomaStatus unknownNCT00293475Phase 1/2
• G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic DisordersTerminatedNCT00253552Not applicable
• Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS LymphomaCompletedNCT00074191Phase 2
• Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS LymphomaCompletedNCT00074178Phase 2